KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2017 - 2018)

Historic Other Accumulated Expenses for Alnylam Pharmaceuticals (ALNY) over the last 5 years, with Q4 2018 value amounting to $23.6 million.

  • Alnylam Pharmaceuticals' Other Accumulated Expenses rose 11766.44% to $23.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $23.6 million, marking a year-over-year increase of 11766.44%. This contributed to the annual value of $23.6 million for FY2018, which is 11766.44% up from last year.
  • As of Q4 2018, Alnylam Pharmaceuticals' Other Accumulated Expenses stood at $23.6 million, which was up 11766.44% from $10.9 million recorded in Q4 2017.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other Accumulated Expenses peaked at $25.4 million during Q1 2014, and registered a low of $3.8 million during Q4 2014.
  • Its 4-year average for Other Accumulated Expenses is $13.7 million, with a median of $10.9 million in 2017.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Accumulated Expenses soared by 1659.52% in 2014 and then skyrocketed by 11766.44% in 2018.
  • Alnylam Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $3.8 million in 2014, then surged by 30.38% to $5.0 million in 2015, then soared by 118.69% to $10.9 million in 2017, then skyrocketed by 117.66% to $23.6 million in 2018.
  • Its Other Accumulated Expenses stands at $23.6 million for Q4 2018, versus $10.9 million for Q4 2017 and $5.0 million for Q4 2015.